Barclays PLC Raises Stake in Royalty Pharma plc (NASDAQ:RPRX)

Dec 18, 2024 · Barclays PLC grew its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 16.3% during the third quarter, according to its most recent 13F filing with the SEC.The institutional investor owned 308,887 shares of the biopharmaceutical company's …

3%
OFF

Barclays PLC Raises Stake In Royalty Pharma Plc (NASDAQ:RPRX)

2 weeks from now

marketbeat.com

15%
OFF

Royalty Pharma PLC (RPRX) Q3 2024 Earnings Call Highlights: …

2 weeks from now

Nov 7, 2024 · Royalty Pharma PLC (RPRX) reports robust 15% growth in portfolio and royalty receipts, raises full-year guidance, and continues strategic acquisitions.

yahoo.com

14%
OFF

Royalty Pharma Plc (NASDAQ:RPRX) Is Favoured By Institutional …

2 weeks from now

Dec 24, 2024 · Insider ownership in Royalty Pharma is 14%. To get a sense of who is truly in control of Royalty Pharma plc (NASDAQ:RPRX), it is important to understand the ownership …

yahoo.com

5%
OFF

Royalty Pharma Plc Declares 5% Increase In Quarterly Dividend

2 weeks from now

4 days ago · Royalty Pharma declares a $0.22 dividend per share for Q1 2025, a 5% increase from the previous quarter. ... NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty …

nasdaq.com

55%
OFF

Royalty Pharma Plc (RPRX): A Strategic Investment In Life …

2 weeks from now

Dec 30, 2024 · Royalty Pharma plc (Nasdaq: RPRX) closed December 27 at $25.54, up 0.55% for the day, with after-hours trading slightly declining to $25.50. The stock’s range over the past …

biopharmajournal.com

1%
OFF

Royalty Pharma Plc (NASDAQ:RPRX) Stake Boosted By Geode …

2 weeks from now

Dec 16, 2024 · Geode Capital Management LLC boosted its position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 6.1% in the 3rd quarter, according to its most recent filing …

marketbeat.com

$24.05
OFF

JPMorgan Chase & Co. Trims Stake In Royalty Pharma Plc …

2 weeks from now

Jan 7, 2025 · Royalty Pharma plc has a 12-month low of $24.05 and a 12-month high of $31.66. The firm has a market cap of $15.17 billion, a price-to-earnings ratio of 13.34, a PEG ratio of …

etfdailynews.com

68%
OFF

With 68% Institutional Ownership, Royalty Pharma Plc …

2 weeks from now

Every investor in Royalty Pharma plc (NASDAQ:RPRX) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around …

nasdaq.com

$3
OFF

Royalty Pharma To Buy Its External Manager, Announces $3B Share …

2 weeks from now

3 days ago · Royalty Pharma plc said the Board of Directors has agreed to acquire its external manager, RP Management, LLC. On a financial basis, the acquisition is expected to reduce …

seekingalpha.com

$2.02
OFF

Royalty Pharma Announces $2.025 Billion Strategic Funding …

2 weeks from now

Jun 2, 2021 · NEW YORK, NY, and PLANEGG, GERMANY, June 2, 2021 – Royalty Pharma plc (Nasdaq: RPRX) and MorphoSys AG (FSE: MOR; Nasdaq: MOR) today announced a $2.025 …

royaltypharma.com

8%
OFF

BNP PARIBAS ASSET MANAGEMENT Holding S.A. Raises Stake In …

2 weeks from now

Nov 23, 2024 · BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 58.8% during the third quarter, …

marketbeat.com

$100
OFF

Royalty Pharma Announces Transformative Step In ... - Markets …

2 weeks from now

3 days ago · Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLC; Significant annual cash savings of greater than $100 million …

businessinsider.com

FAQs about Barclays PLC Raises Stake in Royalty Pharma plc (NASDAQ:RPRX) Coupon?

Is Royalty Pharma plc acquiring new royalties?

The company has been active in acquiring new royalties, with a capital deployment of approximately $2.6 billion year-to-date. Royalty Pharma PLC (NASDAQ:RPRX) raised its full-year 2024 guidance, expecting portfolio receipts between $2.75 billion and $2.8 billion. ...

Does Royalty Pharma (RPRX) have a market share in biopharmaceutical royalty transactions?

Market Leadership and Portfolio Diversification: Royalty Pharma PLC ( NASDAQ:RPRX) stands out with an estimated 58% market share in biopharmaceutical royalty transactions from 2012 through 2023, dwarfing its nearest competitor's 8% share. ...

How did Royalty Pharma perform in the third quarter of 2024?

“We delivered strong growth of approximately 15% in Portfolio Receipts in the third quarter of 2024 and are delighted to raise our full year guidance” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. ...

Does JPMorgan Chase own Royalty Pharma plc?

JPMorgan Chase & Co. lessened its holdings in Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 83.3% during the third quarter, HoldingsChannel reports. The institutional investor owned 1,289,418 shares of the biopharmaceutical company’s stock after selling 6,449,863 shares during the quarter. ...

Will Royalty Pharma repurchase shares in 2025?

Royalty Pharma plc’s Board of Directors has approved a $3 billion share repurchase program. Reflecting the company’s confidence in its strong fundamental outlook, the company intends to repurchase $2 billion of shares in 2025, subject to market conditions. ...

How much did Royalty Pharma (RPRX) earn in 2024?

Royalty Pharma PLC (NASDAQ:RPRX) raised its full-year 2024 guidance, expecting portfolio receipts between $2.75 billion and $2.8 billion. The company successfully acquired royalties on three novel therapies, including FDA-approved treatments for schizophrenia, glioma, and ulcerative colitis. ...